Related Experiment Video
Updated: Dec 24, 2025
07:35
Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
Published on: July 8, 2025
928
Lim Kinase1 regulates seizure activity via modulating actin dynamics.
Qian Jiang1, Guo Tang2, Jie Fu1
1Department of Neurology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Neuroscience Letters
|April 8, 2020
Summary
Limbic kinase 1 (LIMK1) is upregulated in epilepsy and influences seizure susceptibility. Targeting LIMK1 impacts actin dynamics and dendritic spine morphology, offering insights into epilepsy mechanisms.
Area of Science:
- Neuroscience
- Molecular Biology
- Epilepsy Research
Background:
- Limbic kinase 1 (LIMK1) is crucial for brain function and dendritic spine formation.
- The precise role of LIMK1 in epilepsy pathogenesis is not well understood.
Purpose of the Study:
- To investigate the mechanism of LIMK1 in epilepsy.
- To explore the relationship between LIMK1, actin dynamics, and dendritic spine morphology in an epilepsy model.
Main Methods:
- Utilized a pentylenetetrazol (PTZ)-kindled epilepsy rat model.
- Performed in vitro experiments on hippocampal neurons.
- Analyzed LIMK1 expression, seizure susceptibility, and actin polymerization markers (p-cofilin).
- Investigated the effects of LIMK1 knockdown and jasplakinolide treatment.
Main Results:
- LIMK1 was upregulated in the hippocampus of PTZ-kindled rats.
- LIMK1 downregulation decreased seizure susceptibility.
- Combined LIMK1 knockdown and jasplakinolide treatment prolonged seizures.
- LIMK1 was linked to actin depolymerization and dendritic spine maturation via p-cofilin regulation in neurons.
Conclusions:
- LIMK1 plays a role in regulating actin dynamics and dendritic spine morphology in epilepsy.
- LIMK1 is involved in kinase signaling and structural plasticity in seizures.
- Findings provide new insights into the mechanisms underlying epilepsy.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
01:20Antiepileptic Drugs: Potassium Channel Activators
529
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
529
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
734
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
734
01:22Amplifying Signals via Enzymatic Cascade
16.7K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
16.7K
01:16Calmodulin-dependent Signaling
5.9K
Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
5.9K
01:07MAPK Signaling Cascades
7.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.7K